Maternal Immune Activation during Pregnancy Alters the Behavior Profile of Female Offspring of Sprague Dawley Rats.
Animals
Behavior, Animal
/ physiology
Disease Models, Animal
Female
Interferon Inducers
/ pharmacology
Poly I-C
/ pharmacology
Pregnancy
Pregnancy Complications
/ immunology
Prenatal Exposure Delayed Effects
/ physiopathology
Prepulse Inhibition
/ physiology
Rats
Rats, Sprague-Dawley
Recognition, Psychology
/ physiology
Schizophrenia
/ physiopathology
Sex Characteristics
Social Behavior
behavior
prepulse inhibition
recognition memory
sex differences
sociability
Journal
eNeuro
ISSN: 2373-2822
Titre abrégé: eNeuro
Pays: United States
ID NLM: 101647362
Informations de publication
Date de publication:
Historique:
received:
07
11
2018
revised:
25
03
2019
accepted:
26
03
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
11
2
2020
Statut:
epublish
Résumé
Sex differences are documented in psychiatric and neurological disorders, yet most preclinical animal research has been conducted in males only. There is a need to better understand of the nature of sex differences in brain disease in order to meet the needs of psychiatric patients. We present the behavior profile of adult female offspring produced using a maternal immune activation (MIA) model where pregnant rats receive an immune stimulant and the offspring typically show various abnormalities consistent with psychiatric illnesses such as schizophrenia and autism. The results in female offspring were compared to a previously published cohort of their male siblings (Lins et al., 2018). We examined prepulse inhibition (PPI), sociability, MK-801-induced locomotor activity, crossmodal object recognition (CMOR), and oddity discrimination; behaviors relevant to the positive, negative, and cognitive symptoms of schizophrenia. No between-treatment differences in PPI or locomotor activity were noted. Tactile memory was observed in the control and treated female offspring, visual recognition memory was deficient in the polyinosinic:polycytidylic acid (polyI:C) offspring only, and both groups lacked crossmodal recognition. PolyI:C offspring were impaired in oddity preference and had reduced preference for a stranger conspecific in a sociability assay. Systemic maternal CXCL1, IL-6, and TNF-a levels 3 h after polyI:C treatment were determined, but no relationship was found between these cytokines and the behavior seen in the adult female offspring. Overall, female offspring of polyI:C-treated dams display an array of behavior abnormalities relevant to psychiatric illnesses such as schizophrenia similar to those previously reported in male rats.
Identifiants
pubmed: 31016229
doi: 10.1523/ENEURO.0437-18.2019
pii: eN-NWR-0437-18
pmc: PMC6477592
pii:
doi:
Substances chimiques
Interferon Inducers
0
Poly I-C
O84C90HH2L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Références
J Pharmacol Exp Ther. 2004 Apr;309(1):267-74
pubmed: 14722325
Behav Brain Res. 2010 Dec 1;213(2):323-7
pubmed: 20471999
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:155-65
pubmed: 25445065
Curr Top Behav Neurosci. 2011;8:141-54
pubmed: 21374020
Biol Psychiatry. 1997 Feb 15;41(4):452-60
pubmed: 9034539
Biol Psychiatry. 2011 Nov 1;70(9):842-51
pubmed: 21816387
Behav Brain Res. 2011 Jun 20;220(1):55-64
pubmed: 21255612
Neurotoxicol Teratol. 2015 Jan-Feb;47:54-65
pubmed: 25450663
Neuropsychopharmacology. 2012 Sep;37(10):2322-31
pubmed: 22669170
Brain Behav Immun. 2014 Nov;42:138-46
pubmed: 24973728
J Neurosci. 2001 Jul 1;21(13):4915-22
pubmed: 11425919
Neuropsychopharmacology. 2010 Nov;35(12):2462-78
pubmed: 20736993
eNeuro. 2018 Dec 28;5(6):
pubmed: 30627657
Brain Behav Immun. 2017 Jul;63:35-49
pubmed: 28189716
Transl Psychiatry. 2014 Jul 29;4:e418
pubmed: 25072323
eNeuro. 2018 Aug 29;5(4):
pubmed: 30225350
Biotech Histochem. 2005 Mar-Apr;80(2):79-87
pubmed: 16195173
Neurosci Biobehav Rev. 2009 Jul;33(7):1061-79
pubmed: 19442688
J Neurosci. 2007 Mar 7;27(10):2548-59
pubmed: 17344392
Schizophr Res. 2015 Aug;166(1-3):238-47
pubmed: 26055633
Neuropsychopharmacology. 2003 Oct;28(10):1778-89
pubmed: 12865897
Nat Rev Neurosci. 2010 Jul;11(7):490-502
pubmed: 20559336
Neuropsychopharmacology. 2008 Oct;33(11):2610-8
pubmed: 18216776
Psychol Med. 2014 Nov;44(15):3249-61
pubmed: 25065485
PLoS One. 2016 Jun 28;11(6):e0158152
pubmed: 27351594
Brain Behav Immun. 2016 Jan;51:240-51
pubmed: 26327125
Transl Psychiatry. 2019 Feb 14;9(1):90
pubmed: 30765690
Synapse. 2012 Aug;66(8):725-37
pubmed: 22473973
Brain Behav Immun. 2016 Nov;58:165-172
pubmed: 27287966
J Psychiatr Res. 2019 Apr;111:96-103
pubmed: 30690329
Behav Brain Res. 2007 Aug 6;181(2):270-7
pubmed: 17553574
J Psychiatr Res. 2004 May-Jun;38(3):335-45
pubmed: 15003440
J Neurosci. 2007 Oct 3;27(40):10695-702
pubmed: 17913903
Int J Dev Neurosci. 2009 Jun;27(4):399-405
pubmed: 19460635
J Neurosci. 2010 Sep 15;30(37):12424-31
pubmed: 20844137
Neuropharmacology. 2012 Mar;62(3):1299-307
pubmed: 21376064
Front Behav Neurosci. 2014 May 07;8:168
pubmed: 24847231
Behav Brain Res. 2011 Nov 20;225(1):382-7
pubmed: 21816179
Behav Brain Res. 2014 Jan 1;258:179-86
pubmed: 24129217
Brain Stimul. 2013 Jul;6(4):490-9
pubmed: 23085443
Exp Neurol. 2017 Oct;296:16-22
pubmed: 28658605
Neuropsychopharmacology. 2002 Feb;26(2):204-15
pubmed: 11790516
J Neurosci. 2016 Jan 27;36(4):1273-89
pubmed: 26818515
Curr Psychiatry Rep. 2002 Dec;4(6):441-8
pubmed: 12441024
J Neuroimmunol. 2018 Oct 15;323:87-93
pubmed: 30196839
J Pharmacol Exp Ther. 1999 Sep;290(3):1393-408
pubmed: 10454519
J Neurosci. 2010 May 5;30(18):6253-61
pubmed: 20445051
Mol Psychiatry. 2018 Aug;23(8):1794-1797
pubmed: 28993711
Brain Behav Immun. 2018 Oct;73:470-481
pubmed: 29920327
J Psychopharmacol. 2013 Sep;27(9):845-53
pubmed: 23863926
Neuropsychopharmacology. 2019 Jan;44(2):245-258
pubmed: 30188509
J Cogn Neurosci. 2010 Nov;22(11):2460-79
pubmed: 19929757
Learn Mem. 2007 Dec 17;14(12):821-32
pubmed: 18086825
Psychopharmacology (Berl). 2003 Sep;169(3-4):308-13
pubmed: 12748757
Trends Neurosci. 2016 Sep;39(9):587-596
pubmed: 27477199
Am J Psychiatry. 2018 Nov 1;175(11):1073-1083
pubmed: 30220221
Psychoneuroendocrinology. 2014 Nov;49:11-25
pubmed: 25038479
Nature. 2014 May 15;509(7500):282-3
pubmed: 24834516
Q J Exp Psychol B. 2005 Jul-Oct;58(3-4):269-82
pubmed: 16194969
Biol Psychiatry. 2006 Mar 15;59(6):546-54
pubmed: 16256957
Neuropsychopharmacology. 2007 Aug;32(8):1791-804
pubmed: 17180123
Dev Psychobiol. 1997 Mar;30(2):141-50
pubmed: 9068968
Neuropsychopharmacology. 2016 Sep;41(10):2455-62
pubmed: 27000940
Psychophysiology. 2004 May;41(3):401-6
pubmed: 15102125
Toxicol Lett. 2007 Nov 1;174(1-3):18-24
pubmed: 17900830
Behav Brain Res. 2008 Jun 26;190(1):156-9
pubmed: 18367260
Science. 2013 May 17;340(6134):811
pubmed: 23687029
Epilepsy Behav. 2013 Oct;29(1):19-27
pubmed: 23920381
Brain Behav Immun. 2018 Oct;73:51-65
pubmed: 29870753
J Neurosci. 2016 Dec 14;36(50):12570-12585
pubmed: 27974613
Trends Mol Med. 2011 Jul;17(7):389-94
pubmed: 21482187
Schizophr Bull. 2011 Nov;37(6):1257-69
pubmed: 20439320
Sci Rep. 2016 Nov 23;6:37580
pubmed: 27876866
Front Behav Neurosci. 2013 Dec 27;7:217
pubmed: 24409130
Neurobiol Learn Mem. 2017 May;141:150-156
pubmed: 28434949
Neuropharmacology. 2012 Mar;62(3):1273-89
pubmed: 21703648
Neurobiol Dis. 2016 Oct;94:106-15
pubmed: 27282256
Neuroscience. 2012 Jan 10;201:184-98
pubmed: 22119062
J Psychiatr Res. 2005 May;39(3):311-23
pubmed: 15725430
Neuropsychopharmacology. 2013 Sep;38(10):1881-8
pubmed: 23612434
Int J Neuropsychopharmacol. 2016 Dec 3;19(11):
pubmed: 27432008
Learn Mem. 2018 Jun 15;25(7):317-324
pubmed: 29907639
Neuroscience. 2015 Feb 26;287:78-92
pubmed: 25528062